Conflict of interest: Nothing to report.
Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab
Article first published online: 17 APR 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 11, pages 2115–2117, November 2014
How to Cite
Jeng, M. R., Fuh, B., Blatt, J., Gupta, A., Merrow, A. C., Hammill, A. and Adams, D. (2014), Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab. Pediatr. Blood Cancer, 61: 2115–2117. doi: 10.1002/pbc.25067
- Issue published online: 21 SEP 2014
- Article first published online: 17 APR 2014
- Manuscript Accepted: 24 MAR 2014
- Manuscript Received: 14 MAR 2014
- KRAS L19F;
- malignant transformation
We describe a child initially diagnosed with multi-focal infantile hemangioma (cutaneous, hepatic, pulmonary), a benign vascular lesion, which underwent malignant transformation to angiosarcoma. The use of anti-angiogenic agents, such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has been reported in adults with angiosarcoma. Treatment with chemotherapy (gemcitabine and docetaxel) and bevacizumab resulted in disease response with progression free survival of 12 months. This report describes the response to chemotherapy and bevacizumab in a child with angiosarcoma and highlights the potential for malignant transformation of benign vascular lesions and the need for careful monitoring. Pediatr Blood Cancer 2014;61:2115–2117. © 2014 Wiley Periodicals, Inc.